Incyte Corporation (INCY) Earnings Call Transcripts
Incyte Corporation's Latest Earnings Call - September 10, 2026
Incyte Corporation's earnings call on September 10, 2026, highlighted significant advancements in its pipeline and a strategic focus on core business growth. The company reported a revenue of $2.5 billion for the quarter, which was in line with expectations, and reiterated its guidance for fiscal year 2026, aiming for a range of $10 billion to $12 billion. Management emphasized the importance of upcoming product launches and the potential of its late-stage pipeline assets to drive future growth, particularly as it approaches the loss of exclusivity for Jakafi.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $2.5B (inline) |
| Fiscal Year Revenue Guidance | $10B - $12B (inline) |
| Core Business Revenue Target | $3B - $4B (positive) |
| Pipeline Assets | 5 (positive) |
| CAGR Target | 15% - 20% (positive) |
| Cash on Balance Sheet | (positive) |
Guidance from management
Management maintained its revenue guidance for fiscal year 2026 at $10 billion to $12 billion and indicated a focus on achieving core business revenue of $3 billion to $4 billion. They expect to provide more detailed guidance as visibility improves in the coming quarters.
What management said
I would just add 1 comment about competitive intensity. I agree with everything that Pablo said. There are very few markets in oncology where it's winner take all. You can look at BCR-able CDK4/6 or EGFR. And if we're 1 of 2. And right now, there are only really 2 companies in late-stage development with a G12D inhibitor in frontline PDAC. And that's Rev Med and insight. It's a first-world problem. I think this will ...
Yes. I think more important than for us to try to convince you that we're better than next or why the most important thing for us is to execute on the plan and expand the indications. And that's what we're doing.
What analysts pressed on
Analysts expressed concerns about the competitive landscape, particularly regarding differentiation in the G12D inhibitor market and the management of adverse events in new therapies. There were also questions about the timeline for regulatory approvals and the potential impact on future earnings.
Main topics on the call
- Pipeline Advancement — Management noted that the pipeline has progressed significantly, stating, "we're in Phase III in all those assets." This includes key candidates like the G12D inhibitor for pancreatic cancer and the TGF-beta by PD-1 bisp...
- Core Business Growth Strategy — CEO Bill Meury outlined a target of achieving $3 billion to $4 billion in core business revenue, stating, "that is essentially the floor for Insight." This growth is supported by multiple product launches over the next 1...
- Regulatory and Clinical Strategy — Management is focused on maintaining study timelines and securing regulatory approvals, with Meury stating, "we have to execute these programs." This includes plans for upcoming trials and potential FDA discussions regar...
- Cash Utilization and Business Development — Management emphasized the strategic use of cash for R&D and business development, with Meury noting, "the first call on capital is making sure that this R&D program... is maximized." They are looking for accretive opport...
Read the full Incyte Corporation transcript (September 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About Incyte Corporation
Incyte Corporation (INCY) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NasdaqGS and is based in US. EarningsCalls.dev maintains a free, full-text archive of its earnings call transcripts — 118 calls on record spanning January 2, 2020 to September 10, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics, free to read or available through our REST API.
Earnings Call History
EarningsCalls.dev has 118 Incyte Corporation earnings call transcripts on record, spanning January 2, 2020 to September 10, 2026. Based on this history, Incyte Corporation reports quarterly. The most recent call on file is dated September 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.
- Ticker
- INCY
- Exchange
- NasdaqGS
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 118
- First call
- January 2, 2020
- Most recent
- September 10, 2026
- Reporting cadence
- quarterly